Grants for Unrestricted

The PRCRP is seeking to advance cancer research through development of early-career investigators. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PIs research and career development. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. This award supports impactful research projects with an emphasis on discovery. The CDA-SO supports an independent, highly accomplished early-career investigator (referred to as a Scholar) to conduct impactful research under the guidance of an experienced cancer researcher (i.e., Career Guide). Scholars are required to participate in the unique, interactive Virtual Cancer Center (VCC) focused on fostering the next generation of cancer researchers. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge research organization to lead cancer research to a new frontier. It is the intention that, through the VCC, collaborations will foster new growth to ensure the research advancements across different cancers. The VCC directorship is awarded through a separate mechanism, the Virtual Cancer Center Directors Award (VCCDA). The VCCDA calls for two established investigators (Director and Deputy Director) to provide intensive mentoring, national networking, collaborations, and a peer group for Scholars. In addition to their Career Guide, Scholars are required to interact with the VCC Director, Deputy Director, and fellow Scholars to include required attendance at in-person meeting with VCC Members annually. The intention of the Scholar Option is to support highly accomplished investigators toward the goal of leadership in cancer. The critical components of the Career Development Award: Principal Investigator: The PI must be an early-career researcher or physician-scientist within 7 years after completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Postdoctoral fellows are not eligible for this award mechanism. The PIs record of accomplishments and the proposed research will be evaluated regarding their potential for contributing to at least one of the FY24 PRCRP Topic Areas. The Scholar must be in a tenure-track position or equivalent position. The Scholar must demonstrate significant accomplishments, including first-author publications, extramural funding (beyond nominal), and show excellence in cancer research as supported by letters of recommendation. The Scholar must have independent laboratory space separate from the Career Guides laboratory or other mentors laboratory. For more information on the eligibility criteria for the Virtual Cancer Center Scholar Option, refer to Section II.C.1. Career Guide: The Scholar must designate a Career Guide. The Career Guide must be an experienced cancer researcher, as demonstrated by a strong record of funding and publications. In addition, the Career Guide must demonstrate a commitment to advancing the PIs career in cancer research and be committed to fully participating in the VCC and potentially serving on the VCCs Advisory Board as requested by VCC Leadership. Career Development Plan: A career development plan is required and should be prepared with appropriate guidance from the Career Guide. The career development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, further independence, and expertise to advance their career at the forefront of cancer research in at least one of the FY24 PRCRP Topic Areas. Milestones: The Scholar must show career milestones and pathways toward achieving the milestones. The Scholar should demonstrate clear commitment to at least one of the FY24 PRCRP Topic Areas through a career development plan designed to enhance further networking and collaboration. Impact: The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient care. Impactful research will accelerate the movement of promising ideas in cancer research into clinical applications.

Dear Interested Parties: Pursuant to FAR 52.215-3 Request for Information (Oct. 1997), the United States Government, represented by The United States Agency for International Development (USAID) South Sudan Mission, is issuing the subject Request for Information (RFI) to all interested public and private entities on critical areas to support the delivery of integrated HIV care and treatment services for general and key populations including other disadvantaged populations such as people with disability and migrants. The Purposes of the care and treatment activity are: Improve equitable access to and use of quality comprehensive HIV prevention, testing, care, and treatment services for all South Sudanese. Provide quality comprehensive services for key populations at the current locations and expand as needed. Develop local partner capacity and prepare local partners to manage direct awards. This RFI is open for comments from any local Civil Society Organization (CSO), South Sudanese Organization, US, or non-US. Organization. This is an RFI, not a Request for Application (RFA). Do not submit any applications or proposals at this time; only the information requested per Attachment 1- RFI Questions for respondents and submission instructions- and all responses will be treated confidentially. Responses to this RFI may be used to help determine critical areas to support the delivery of integrated HIV care and treatment services for general and key populations, including other disadvantaged populations such as people with disability and migrants. USAID may revise the structure and concept of the activity based on the comments received, but it is not obligated to do so. All comments must be submitted electronically, with the subject of "RFI: USAID/South Sudan Care and Treatment Activity," no later than the date and time stated above. Please note: This is NOT a solicitation. This RFI is issued solely to gather information and innovative ideas for new design and planning purposes. This RFI does not constitute a Request for Applications (RFA), Request for Proposal (RFP), Notice of Funding Opportunity (NOFO), or a commitment to issue an RFA/RFP/NOFO in the future. USAID may release a full solicitation later through the US Government portal at beta.sam.gov or www.grants.gov. If you have issues accessing the link, please contact Michael Loro at mloro@usaid.gov for a pdf version Thank you for your interest in sharing your views and innovative ideas with the USAID/South Sudan Mission. Sincerely, Lesley Stewart Contracting and Agreement Officer USAID/South Sudan N.B if you have issues accessing the link, please contact Michael Loro @mloro@usaid.gov for a pdf version

The purpose of this RFI is to solicit feedback from industry, academia, research laboratories, government agencies, and other stakeholders on issues related to U.S domestic wind turbine blade manufacturing. EERE is specifically interested in information on current domestic blade manufacturing challenges, future domestic blade manufacturing needs, workforce, and stakeholder strategy development. This is solely a request for information and not a Funding Opportunity Announcement (FOA). EERE is not accepting applications. This is an RFI only. DOE will not pay for information provided under this RFI and no project will be supported as a result of this RFI. This RFI is not accepting applications for financial assistance or financial incentives. DOE may or may not issue a Funding Opportunity Announcement (FOA) based on consideration of the input received from this RFI. Responses to this RFI must be submitted electronically to WindEnergyRFI@ee.doe.gov no later than 5:00pm (ET) on 7/30/2024. Responses must be provided as attachments to an email. To view the entire RFI document, visit the EERE Exchange Website at https://eere-exchange.energy.gov

Notice of Intent (NOI) for Funding Opportunity Announcement DE-FOA0003334 titled Offshore Wind National and Regional Research and Development. The Office of Energy Efficiency and Renewable Energy (EERE) intends to issue, on behalf of the Wind Energy Technologies Office (WETO), a Funding Opportunity Announcement (FOA) entitled Offshore Wind National and Regional Research and Development. This notice of intent (NOI) is issued so that interested parties are aware of EEREs intention to issue this FOA in the near term. All the information contained in this NOI is subject to change. EERE will not respond to questions concerning this NOI. Once the FOA has been released, EERE will provide an avenue for potential applicants to submit questions. Complete information, including the full Notice of Intent, can be found on the EERE Exchange website: https://eere-exchange.energy.gov/

RFI Number: 7200AA24RFI00017Issuance Date: April 22, 2024Closing Date: May 20, 2024 5:00pm EDTSubject: Accelerating HIV Vaccine Research and Development in Low- and Middle-Income Countries (LMIC)To All Interested Respondents/Parties:The United States Agency for International Development (USAID) Bureau for Global Health (GH) is publishing this Request for Information (RFI) to obtain information and input that will be used to help make planning decisions. It may inform the design of future activities related to accelerating HIV vaccine research and development in low- and middle-income countries.This RFI is issued solely to collect expert inputs for information-gathering and planning purposes. This RFI does not constitute a Notice of Funding Opportunity (NOFO) or a Request for Proposals (RFP).Please also note the following:(a) responding to this Notice will not give any advantage to any organization or individual for any subsequent competition;(b) proprietary information should not be sent;(c) responses are not offers/applications and cannot be accepted by the U.S. Government to form a binding contract/award;(d) responses to this RFI are strictly voluntary, and USAID will not pay respondents for information provided in response to this RFI;(e) USAID reserves the right to, or not to, incorporate any/some/none of the comments received from RFI into subsequent solicitations or design documents and(f) applications or resumes will be discarded and should therefore not be included in your response.USAID posts its competitive business opportunities on www.sam.gov and www.grants.gov. This RFI does not restrict the Governments approach to a future solicitation or NOFO. It is the potential responders responsibility to monitor the site for the release of any further information.Questions regarding this announcement will not be accepted or answered. Not responding to this request does not preclude participation in any future solicitation, if any is issued. No basis for claims against the U.S. Government shall arise as a result of a response to this request for information or from the U.S. Governments use of such information.Submission Instructions:Only electronic submissions will be accepted. Responses to this RFI must be written in English.Respondents will only receive an electronic confirmation acknowledging receipt of their response; theywill not receive individualized feedback on any suggestions.USAID is requesting the public to submit short submissions outlining recommendations or otherinformation pertinent to the questions noted below. Responses should note the question numberaddressed and clearly relate back to the questions listed below, but responses do not need to addressevery question listed. All responses should provide sufficient detail and justification explaining why acertain recommendation is offered. Please also provide your name, title, organization, and contactinformation in the response.All submissions must adhere to the following format to ensure an efficient review: Must be written in English, size 11 Calibri font, not to exceed 20 pages total. The graphics subtextmay use a smaller font size. Submission file should be in PDF or Microsoft Word format. Submission file should be saved as ;lt;Entitys name;gt; Response to RFI 7200AA24RFI00017. The subject line for the submission email subject line must include Response to USAID/GHs RFI- Accelerating HIV Vaccine Research and Development in LMIC Must be submitted to Ms. Simone Cho at scho@usaid.gov with a copy to Mr. Elton Fortson atefortson@usaid.gov by the closing date and time noted at the beginning of this letter.Thank you for your interest in responding to this RFI. To learn more about partnering with USAID, pleasevisit www.work with usaid.gov.

Ladies/Gentlemen: The United States Agency for International Development (USAID) is seeking applications for a cooperative agreement from qualified entities to implement the Promoting Human Rights in Armenia Activity. Eligibility for this award is not restricted; both qualified U.S. and non-US organizations are eligible to apply. USAID intends to make one award to the applicant who best meets the objectives of this funding opportunity based on the merit review criteria described in this NOFO subject to a risk assessment. Eligible parties interested in submitting an application are encouraged to read this NOFO thoroughly to understand the type of program sought, application submission requirements and selection process. Subject to the availability of funds, the total estimated amount for this five-year activity is $10,000,000. To be eligible for the award, the applicant must provide all information as required in this NOFO and meet eligibility standards in Section C of this NOFO. This funding opportunity is posted on www.grants.gov, and may be amended. It is the responsibility of the applicant to regularly check the website to ensure they have the latest information pertaining to this notice of funding opportunity and to ensure that the NOFO has been received from the internet in its entirety. USAID bears no responsibility for data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the NOFO, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at support@grants.gov for technical assistance. USAID will not make an award to an applicant unless the applicant has complied with all applicable unique entity identifier and System for Award Management (SAM) requirements detailed in Section D. 6. (g) The registration process may take many weeks to complete. Therefore, applicants are encouraged to begin registration early in the process. Please send any questions to the points of contact identified in Section D. The deadline for questions is shown above. Responses to questions received prior to the deadline will be furnished to all potential applicants through an amendment to this notice posted to www.grants.gov. USAID currently anticipates doing only one round of Q However, interested applicants should feel free to submit additional questions to USAIDs POCs listed in Section D. If additional questions are received after amendment 1 is issued that merit answering, USAID may decide to do a second round of Q and issue a second amendment to this NOFO. Issuance of this notice of funding opportunity does not constitute an award commitment on the part of the Government nor does it commit the Government to pay for any costs incurred in preparation or submission of comments/suggestions or an application. Applications are submitted at the risk of the applicant. All preparation and submission costs are at the applicants expense.

The "DoD Multiple Sclerosis, Early Investigator Research Award" is a grant designed to support early-stage researchers in developing a Multiple Sclerosis-focused research project under the guidance of experienced mentors, with the aim of advancing their careers and contributing to the understanding and treatment of Multiple Sclerosis.

The United States Agency for International Development (USAID) Mission in Jordan issues a Request for Information (RFI) to collect data to inform the design of a new early childhood education and workforce activity. This is a Request for Information (RFI), providing information to parties interested in USAIDs support in Jordan, and seeks to collect any information and suggestions about USAIDs planned programming. Information collected is intended to contribute to the Missions activity design and development for an intended future Request for Proposal (RFP) or Request for Application (RFA).Please see the attached RFI No. 72027824RFI00004 for more information.

The "DoD Multiple Sclerosis, Investigator-Initiated Research Award" is a grant that supports high-quality research projects aimed at improving understanding, patient care, and quality of life for those with Multiple Sclerosis, and encourages applications from both established and early-career investigators, with a focus on projects that can provide relevant preliminary or published data.

This grant provides funding for organizations to develop solutions addressing the root causes of irregular migration from Central America to the United States, targeting countries like Guatemala, Honduras, and Costa Rica.

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope of previous clinically focused award mechanisms.The FY24 MBRP PCRA intends to bridge the gap between research, practice, and policy by building a knowledge base that provides clinically useful findings about how interventions, clinical practices/guidelines, tools, and policies can be deployed to targeted populations at the appropriate time at the point of need. Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research. Applications may propose prospective or retrospective research involving human subjects, human subject data/records, and human anatomical substances.The FY24 PCRA may support studies focusing on the following (not all inclusive): Research that accelerates the uptake and implementation of evidence-based research into clinical practice Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines Analysis of existing clinical data or clinical data resources to inform clinical practice Modification of established clinical tools for their intended population or environment Analysis of existing clinical tools to maximize patient-relevant outcomes Identification and analysis of the circumstances that create a need to stop or reduce (de-implement) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful Analysis of burn outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvements The following are important aspects of the FY24 MBRP PCRA: Precision Medicine Approaches: When appropriate, the MBRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individuals unique characteristics. Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date. Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the clinical implementation of therapeutics, technologies, or clinical practice guidelines that advance the care of burn-injured casualties.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or VA Resources: If the proposed research involves access to active-duty military and/or VA patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 2.Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human data,human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight (OHRO), prior to research implementation. This administrative review requirement is in addition to the local IRB or Ethics Committee (EC) review. Local IRB/EC approval at the time of application submission is not required; however, local IRB/EC approval is necessary prior to OHRO review. Allow up to 3 months to complete the OHRO regulatory review and approval process following submission of all required and complete documents to the OHRO. Refer to the General Application Instructions, Appendix 1, and the OHARO web pagehttps://mrdc.health.mil/index.cfm/collaborate/research_protections for additional information.If the proposed research involves more than one institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.The types of awards made under the program announcement will be assistance agreements. An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Patient-Centered Research Award should not exceed $2.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.4M to fund approximately two Patient-Centered Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Santa Clara County District Attorney’s Office is offering the Asset Forfeiture for Racial Justice Grant Program, aligning with District Attorney Jeff Rosen’s "Bend the Arc" reforms. The core mission of these reforms is to combat racial discrimination and disproportionality, thereby fostering equity within the criminal justice system. This grant program is a direct extension of this mission, seeking to support initiatives that address and rectify racial inequities in the community. The program aims to leverage asset forfeiture funds to create positive change and promote a more just and equitable society within Santa Clara County. The target beneficiaries of this program are marginalized communities within Santa Clara County, particularly those affected by racial inequities in the criminal justice system. The grant funding is specifically designated to benefit these communities, ensuring that the resources are directed to where they are most needed. The overarching impact goal is to reduce racial disparities and promote equity, ultimately leading to a more fair and inclusive community. This is achieved by supporting programs, events, and causes that directly confront and resolve issues of racial injustice. The program prioritizes initiatives that successfully address racial inequities in the community. Grant requests are considered for programmatic support, events, and various causes that align with this focus. A crucial guideline is that the grant funding cannot be used retroactively; the award must be granted before the project or event commences. This ensures that the funding supports future-oriented efforts to address current and ongoing racial disparities. Expected outcomes include tangible progress in reducing racial discrimination and disproportionality within the criminal justice system and the broader community. While specific measurable results are not explicitly detailed in the provided information, the focus on "successfully addressing racial inequities" implies a commitment to demonstrable positive change. The program's strategic priority is to advance the "Bend the Arc" reforms, utilizing grant funding as a tool to implement a theory of change that centers on community-based solutions to systemic racial injustices. The maximum award per recipient is up to $5,000, and each organization, individual, or group may submit only one application, ensuring a broad distribution of funds to various impactful initiatives.

30 MAY 2024: The purpose of this amendment is to provide the finalized ISO and to provide the Administrative and National Security Form. 17 MAY 2024: The purpose of this amendment is to provide an updated Draft ISO, and the cost proposal worksheets. 22 APRIL 2024: The purpose of this amendment is to extend the Full Proposal due date to August 20, 2024, at 5:00pm, ET. 10 APRIL 2024: The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. Interested parties are invited to review the attached PRINT Innovative Solutions Opening (ISO) ARPA-H-SOL-24-101. 27 MARCH 2024: The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. ARPA-H will host a Proposers Day on May 07, 2024. The event will allow for both in-person and virtual participation and is intended to facilitate teaming and foster a greater understanding of the PRINT Program. The closing date for registration is April 30, 2024, 1:00 PM ET. In-person attendance is first-come, first-served or when capacity is reached. After reviewing the attached Proposers Day information, interested parties are encouraged to register at the link below. https://arpa-h.gov/research-and-funding/programs/print Solution Summary Due Date and Time: May 28, 2024, 9:00 AM ET Proposals will be by invitation only. Proposal Due Date and Time: August 20, 2024, 9:00 AM ET For more information about ARPA-H, please visit https://arpa-h.gov

This grant seeks input from stakeholders to design a project that will enhance agricultural growth and food security in Sylhet Division, Bangladesh, addressing local challenges such as poverty, malnutrition, and climate change.

The purpose of the new Countering Trafficking in Persons and Support to Vulnerable Populations (CTIP/V) activity is to (1) prevent trafficking in persons (TIP) through a strengthened comprehensive, government-led counter-trafficking response and (2) to ensure nationwide access to trauma-informed and survivor-centered recovery and reintegration services for victims of trafficking, exploitation, gender-based violence (GBV) (particularly intimate-partner violence and conflict-related sexual violence (CRSV)), and detention/torture. This Activity has four main objectives: Objective 1: Understanding of TIP risks and prevention strategies increased, especially among government officials and vulnerable groups. Objective 2: Sustainability and availability of comprehensive, trauma-informed protection services increased to ensure seamless access for victims of trafficking and war-related trauma across Ukraine. Objective 3: Prosecution of those willfully engaged in TIP strengthened. Objective 4: Partnerships developed and strengthened across government, civil society, and socially responsible businesses to counter TIP at the decentralized, national, and European regional levels. USAID intends to award one (1) Cooperative Agreement pursuant to this NOFO. Subject to funding availability and at the discretion of the Agency, USAID intends to provide no more than $24,000,000 in total USAID funding over a five (5) year period.

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and pre-cancer in underserved populations who do not have adequate access to cancer early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers.

This Notice of Funding Opportunity (NOFO) expands national-to-subnational coordination to detect outbreaks and manage responses earlier, advance the National Public Health Institute of Liberias (NPHIL) broad vision for Liberias emergency response framework (ERF), and develop a national emergency management training program to support counties response capacity.

The purpose of Amendment 000002 is to revise the Funding Opportunity Announcement to revise Section I.B. Area of Interest 1 - General Requirements Item 11. - Definition of Project Progress Cells (PPCs) and Project Completion Cells (PCCs).

The grant titled "Notice Of Intent (NOI) To Issue Funding Opportunity Announcement De-Foa-0003183: Bipartisan Infrastructure Law (BIL) Section 41007(B)(1): Aerodynamics For Extreme-Scale Offshore Wind Performance And Survival (AESOPS)" aims to provide up to $5.1 million in funding to develop and validate aerodynamic design tools for large-scale offshore wind turbines, collect data on wind turbine airfoil behavior, and create reliable models to reduce the risk and cost of developing and deploying these turbines.

Invasive species pose a significant threat to the ecological, economic, and cultural integrity of Americas lands and waters and the communities they support. Once invasive species are established, it is often challenging and costly to control or eradicate those infestations. In some cases, however, eradication the removal or destruction of an entire population of invasive species from a defined area is both possible and feasible, resulting in substantial ecological and economic benefits. This can include eradication of a founding population of invasive species (e.g., a newly introduced species to a specific area) or eradicating a well-established population. Eradication, while it represents the ideal outcome in most cases, requires consideration of the available eradication techniques, cost, likelihood of success, likelihood of re-invasion, public support, complexity of environmental compliance, and availability of resources. This latter consideration is frequently a barrier to implementing eradication measures that can lead to restoring ecosystem health.Furthermore, successful eradication efforts are often dependent on the use of integrated pest management (IPM) strategies, making well informed decisions, and applying a collaborative approach. IPM is defined as an approach to managing pests that uses biological, cultural, physical, and chemical tools in a way that minimizes health, environmental, and economic risks. Collaboration with relevant parties, such as state, federal, local, tribal, territory, private, and other land managers, is often essential for successful eradication projects.For eradication to be an option, resource managers must have access to effective tools. Therefore, it is important to support both on-the-ground eradication efforts and also the research into and development of tools where they do not exist. DOI encourages leveraging science and technology to increase the likelihood of eradication of invasive species and increase the likelihood of long-term success. As such, proposals will be considered for on-the-ground projects that eradicate an invasive species or those projects that advance research that increases the effectiveness and near-term availability of eradication tools. For example, studies that lead to the development of genetic interventions and physical, mechanical, chemical, and biological eradication tools would be eligible.Examples of the type of work being targeted for this Invasive Species Eradication Funding Opportunity include:Eradication of the invasive annual grass Cenchrus spp. A Weed Risk Assessment for the invasive annual grass Cenchrus spp. in Hawaii identified the species as high risk for many reasons. It thrives and spreads in tropical climates. It is an invasive plant that affects native coastal vegetation and seabird habitat. It has spiny burs that disperse easily via clothing or feathers, reproduces by prolific seed production, and is easily spread by high winds and storms. It reaches maturity in less than one year and persists in the seedbank for one to five years. Cenchrus spp. was introduced to the remote island of Nihoa, a volcanic remnant in the Hawaiian Archipelago with many geographically distinct species including two endemic and endangered passerines and three endemic and endangered plants. Early detection and monitoring indicated that the Cenchrus spp. infestation on Nihoa dramatically increased from just seven plants observed in 2017 to over 600 plants in 2018. This expansion indicated that it was initiating its ascent of the exponential growth curve common in invasive species. Eradication efforts are underway to eradicate Cenchrus spp. from Nihoa via an integrated pest management process (e.g., physical and chemical treatments) coupled with rigorous biosecurity measures to prevent reinvasion.Research on the use of YY technology for invasive fish eradication. The Western Association of Fish and Wildlife Agencies initiated, in 2018, the YY Male Consortium (Consortium) with funding from 13 western states. The Consortium is building upon the work initiated by the State of Idaho to develop YY male broodstock for invasive brook trout. They are developing research broodstock for five additional regionally invasive species, including the common carp, walleye, lake trout, brown trout and Northern pike. Ongoing field evaluations of eradication programs using YY male brook trout in several western states indicate suppression is happening as modeled. In addition, populations in smaller systems are on the verge of documenting total eradication. This work combines multiple control tools using the principles of integrated pest management by suppressing invasive brook trout populations annually through mechanical and/or chemical control, and then stocking the equivalent number of YY males to replace those removed. YY males breed with the wild females, producing only YY males, leading ultimately to an all YY male population and population eradication. Note: This Invasive Species Eradication Funding Opportunity is separate from the Rapid Response Fund for Aquatic Invasive Species Notice of Funding Opportunity (grants.gov announcement number F24AS00175). The Rapid Response Fund for Aquatic Invasive Species is intended to support the planning and deployment of responses to newly detected populations of aquatic invasive species in pursuit of eradicating the population before it becomes established and spreads. This Invasive Species Eradication Funding Opportunity, however, is open to all taxa (see Eligible Taxa section) and can be used for eradication of newly detected populations of terrestrial invasive species, eradication of well-established populations of aquatic or terrestrial invasive species, or for research that advances tools for effective eradication of aquatic or terrestrial invasive species. Bipartisan Infrastructure Law (BIL) Ecosystem Restoration Program and DOI PrioritiesThe Bipartisan Infrastructure Law (also referred to as BIL, or the Infrastructure Investment and Jobs Act (IIJA)), Section 40804 (Ecosystem Restoration) provided funding to DOI for invasive species detection, prevention, and eradication, including conducting research and providing resources to facilitate detection of invasive species at points of entry and awarding grants for eradication of invasive species on non-Federal land and on Federal land. This Invasive Species Eradication Funding Opportunity aims to meet BILs direction to offer grants for eradication of invasive species.This funding opportunity also advances DOIs policy regarding invasive species management (524 DM 1) which identifies eradication undertaken in a cost-effective and environmentally sound manner as one objective of an integrated pest management approach. Additionally, it advances Goal 4 of the DOIs Invasive Species Strategic Plan for 2021-2025 to cost-effectively control or eradicate established invasive species populations to reduce impacts and help restore ecosystems.For this funding opportunity, collaboration with one of DOIs Keystone Initiatives is encouraged, as appropriate. DOI prioritized these Keystone Initiatives as focal areas for transformational conservation efforts across the nation. The Keystone Initiatives advance the Restoration and Resiliency Framework and include:Gravel to GravelGrasslandsHawaiian Forest BirdsKlamath BasinSagebrush EcosystemSaltmarsh, andAppalachiaPurpose and Program Grant Requirements:In Fiscal Year 2024, DOI prioritized BIL funds to establish this Invasive Species Eradication Funding Opportunity within the existing authorities of DOI, to be administered by the USFWS in collaboration with DOI bureaus. Accordingly, the DOI bureaus, through the USFWS, invite proposals to support the eradication of a newly introduced or established species in terrestrial or aquatic habitats of the United States, including the U.S. territories (aquatic habitats include freshwater, wetland, riparian, estuarian, and marine). While preference will be given to proposals that result in eradication of invasive species, research proposals that advance research that increases the effectiveness and availability of eradication tools will be considered. Eradication is defined as the removal or destruction of an entire population of invasive species. For the purposes of this funding opportunity, this means the elimination of all individuals of a distinct population in a geographically defined area that is not contiguous or connected (via natural dispersal) with other populations and that is surrounded by naturally occurring or human-made barriers sufficiently effective to prevent reinvasion as verified using monitoring and inventories. Projects targeted at eradicating a founding population of a terrestrial invasive species or those eradicating established populations of aquatic or terrestrial invasive species will be considered. Eradication can be a key resource management step that then allows other resource management objectives to be achieved, such as habitat restoration or the recovery of Threatened and Endangered Species. This funding opportunity recognizes that eradication of a widespread established invasive species is possible and can be successful late in the invasion stages, but it requires strategic approaches (such as by using IPM) and targeted investments. The intent of this funding opportunity is to promote and invest in those projects with a high likelihood of achieving eradication success and in those that have existing partnerships and plans in place. NOTE: Projects responding to founding populations of aquatic invasive species within the early detection and rapid response context should instead apply for funding through the Rapid Response Fund for Aquatic Invasive Species. Projects addressing established aquatic invasive species infestations with a high likelihood of eradication can apply for this Eradication Funding Opportunity. Proposals submitted for this opportunity should address how the proposed project supports DOIs mission, especially helping to protect vulnerable, high priority, or protected species or areas. Proposals that service underserved, or historically disadvantaged communities are also encouraged. These will be considered among the grant review criteria listed under the Application Review Information section later in this document.